Le Lézard
Classified in: Health, Science and technology
Subjects: PDT, TDS, BFA

MIJ Korea Unveils First Digital Tinnitus Care Smartphone App in CES 2021


CHUNCHEON, GANGWON-DO, South Korea, Jan. 15, 2021 /PRNewswire/ -- MIJ introduce a tinnitus care solution, CARE4EAR in CES 2021.

Experience the interactive Multimedia News Release here:
https://www.multivu.com/players/English/8841351-mij-korea-care4ear-tinnitus-ces-2021/

CARE4EAR is a smartphone app to help tinnitus patients. CARE4EAR allows users to take the self-hearing test and self-tinnitus test without a helping hand.

CARE4EAR applied the mixing-point sound therapy method. Although sound therapy was first introduced in the 70s and was proven its effectiveness, it was difficult for many tinnitus patients to get the benefit of personal care due to technical or real-environmental issues. MIJ has developed a tinnitus care solutions system since 2018 to solve these problems and finally released the tinnitus care app 'CARE4EAR' that makes tinnitus care easy to use anytime and anywhere.

CARE4EAR users first test their hearing, and then check the type, frequency, and intensity of the tinnitus sound. Based on the hearing test and tinnitus test results, users can have a customized individual care sound for tinnitus. Listening to this customized sound on daily basis can improve tinnitus. The developer suggests listening to the tinnitus care sound for 4hrs. a day, 6 months or more.

MIJ proved the effectiveness of its tinnitus care solution through clinical trials and researches, conducted jointly with Hallym University, Korea in 2019. In 2020 CARE4EAR continued further research in context with care app and a significant positive effect on tinnitus care has been demonstrated.

MIJ is expected to launch big events that will take place online for the first time this year from January 11 to January 14 amid COVID 19 - a pandemic situation faced by the global market. We cordially invite everyone to join this memorable occasion by visiting CES website.

CES2021 visitors will be able to access CES2021 events contents online until February 15, 2021.

The Major aim of developing CARE4EAR is to provide an outstanding user experience for caring hearing capacity and tinnitus of our customers.

You can learn more about CARE4EAR at http://www.mijkorea.com/eng/product4.php

If you suspect yourself you may have tinnitus, care your ear with CARE4EAR

 

Tinnitus can impact your life, Get the Solution!

SOURCE MIJ Co., Ltd.


These press releases may also interest you

at 10:02
Completion of Largest Capacity GMP Run Marks New Standard in Biologics Manufacturing
Boston Institute of Biotechnology, LLC (BIB) in collaboration with BIBo-Biopharma, proudly announces the successful completion of a groundbreaking 30,000L fermentation run, marking a significant milestone in biotechnology history....

at 10:00
Missing Indigenous children: a third review since the Act came into force
Minister Responsible for Relations with the First Nations and the Inuit Ian Lafrenière today submitted in the National Assembly the third annual report on the administration of the Act to authorize the communication of personal information to the...

at 10:00
Cobb Outpatient Detox Opens New Outpatient Drug and Alcohol Detox Facility in Marietta, GA
Cobb Outpatient Detox has opened a new facility in Marietta, GA, providing outpatient drug and alcohol detox services. The center aims to assist individuals in overcoming addiction while balancing their work and family commitments. Located near major...

at 10:00
PER PERSON HEALTH CARE SPENDING EXCEEDED $6,700 IN 2022
A new report from the Health Care Cost Institute (HCCI) shows that, even with fluctuations in 2020 and 2021, per person health care spending grew from 2018 to 2022. Over the five years, average prices increased by 14% and utilization went up by about...

at 10:00
BioInnovation Institute & Science announce the launch of the Translational Medicine Prize for Innovations in Women´s Health and Gender Medicine
BioInnovation Institute (BII), an international non-profit foundation, incubating and accelerating world-class life science research, today announces the launch of the BII & Science Translational Medicine Prize for Innovations in Women´s Health and...

at 10:00
2024 ASCO | Mabwell to Present Clinical Data of 9MW2821 in Multiple Advanced Solid Tumor
Mabwell (688062.SH), an innovation-driven biopharmaceutical company with an entire industry chain, announced that the Phase I/II clinical study results of the novel Nectin-4-targeting ADC 9MW2821 for multiple advanced solid tumors will be presented...

More news about Health...


News published on and distributed by: